



17 April 2025

Sydney, Australia

## Nyrada General Meeting Results

**Nyrada Inc (ASX:NYR)**, a drug discovery and clinical development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers, announces the results of today's General Meeting of CDI Holders / Shareholders of the Company.

***All resolutions (with the exception of Resolution 9) were passed and decided by way of a poll.***

***Resolution 9 "Approval of Grant of Warrants to Ian Dixon, Director of the Company" was not carried decided by way of a poll.***

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

-ENDS-

### About Nyrada Inc.

Nyrada Inc. is a biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection, and is being evaluated in a Phase I study. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.*

### Investors and Media:

Dimitri Burshtein

T: 02 9498 3390

E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)



### Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only

# Disclosure of Proxy Votes

Nyrada Inc

Extraordinary General Meeting

Thursday, 17 April 2025



GPO Box 5193, Sydney, NSW 2001  
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)  
F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)  
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of Prior Issue of 27,416,668 CDIs under ASX Listing Rule 7.4	P	37,778,555	36,329,160 96.16%	1,209,439 3.20%	33,383,245	239,956 0.64%	36,569,116 96.80%	1,209,439 3.20%	33,383,245	Carried
2 Ratification of Prior Grant of 2,500,000 Options under ASX Listing Rule 7.4	P	48,723,649	47,192,273 96.86%	1,291,420 2.65%	33,388,245	239,956 0.49%	47,432,229 97.35%	1,291,420 2.65%	33,388,245	Carried
3 Approval of Issue of CDIs to John Moore, Chairman and Director of the Company	P	50,956,561	49,169,185 96.49%	1,547,420 3.04%	34,956,001	239,956 0.47%	49,409,141 96.96%	1,547,420 3.04%	34,956,001	Carried
4 Approval of Issue of CDIs to Marcus Frampton, Director of the Company	P	51,410,909	49,623,533 96.52%	1,547,420 3.01%	34,501,653	239,956 0.47%	49,863,489 96.99%	1,547,420 3.01%	34,501,653	Carried
5 Approval of Grant of Warrants to John Moore, Chairman and Director of the Company	P	84,329,806	49,169,185 58.31%	34,920,665 41.41%	1,582,756	239,956 0.28%	49,409,141 58.59%	34,920,665 41.41%	1,582,756	Carried
6 Approval of Grant of Warrants to Christopher Cox, Director of the Company	P	83,977,562	48,816,941 58.13%	34,920,665 41.58%	510,000	239,956 0.29%	49,056,897 58.42%	34,920,665 41.58%	510,000	Carried
7 Approval of Grant of Warrants to Marcus Frampton, Director of the Company	P	84,784,154	49,623,533 58.53%	34,920,665 41.19%	1,128,408	239,956 0.28%	49,863,489 58.81%	34,920,665 41.19%	1,128,408	Carried
8 Approval of Grant of Warrants to Dr. Rüdiger Weseloh, Director of the Company	P	85,535,896	50,270,012 58.77%	35,025,928 40.95%	376,666	239,956 0.28%	50,509,968 59.05%	35,025,928 40.95%	376,666	Carried



For personal use only

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of Grant of Warrants to Ian Dixon, Director of the Company	P	73,360,452	34,293,900 46.75%	38,826,596 52.93%	12,552,110	239,956 0.33%	34,533,856 47.07%	38,826,596 52.93%	12,552,110	Not Carried

